The AnteoTech (ASX:ADO) share price closed 43% higher today

The AnteoTech share price boomed over 40% higher today. Let's check out the company's latest announcement to see what's up.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Anteotech Ltd (ASX: ADO) share price gained a whopping 43.18% today, closing the day trading at 32 cents.

AnteoTech is a surface chemistry company with intellectual property in its core technology product groups. These include AnteoCoat, AnteoBind and AnteoRelease. The company's customers operate in the life sciences, diagnostics, energy and medical devices markets.

With no recent company announcements, let's take a look at what could be driving the AnteoTech share price.

AnteoTech share price zooms after Ellume secures US contract

Earlier this month, AnteoTech announced that its client, Ellume, had signed a deal with the US Defence Department for emergency use authorisation of its COVID-19 at-home test.

Ellume integrates AnteoBind technology in its proprietary quantum dot diagnostics platform.

The Ellume COVID-19 home test, incorporating AnteoBind, is the first non-prescription over-the-counter self-test authorised by the US Food and Drug Administration (FDA) for emergency use.

AnteoBind is a key element of AnteoTech's own COVID-19 Antigen Rapid Test currently in development and several other assays marketed globally.

AnteoTech advised that it has worked closely with Ellume over recent months to ensure it could supply the required volumes of AnteoBind.

The company expects that Ellume's requirement for AnteoBind will increase modestly over coming months as supply to the US markets takes off.

Words from the CEO

Commenting on the Ellume agreement, AnteoTech CEO Derek Thomson said:

We are delighted to be involved with Ellume's success and we congratulate the company on their announcement.

Ellume was the original seed customer in AnteoTech's strategy to demonstrate the value that AnteoBind can bring to assay development and it is pleasing to see that strategy now delivering market recogition.

I commend the work of AnteoTech's Life Science team under the leadership of Charlie Huang for their continued work to make AnteoBind a key element in the development of diagnostic products in global markets.

The AnteoTech share price has exploded more than 648% higher over the previous 12-month period.

Motley Fool contributor Gretchen Kennedy has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Share Market News

Testing again

Read more »

Share Market News

Aaron Test 2

Read more »

Share Market News

Aaron Test

Read more »

Share Market News

JP Test

Read more »

Share Market News

JP Test

Read more »

Portrait of Discovery Fund portfolio managers Mark Devcich and Chris Bainbridge
Share Market News

Test

Portfolio managers Mark Devcich (left) and Chris Bainbridge. Image source: Discovery Fund test test

Read more »

a man in a hoodie grins slyly as he sits with his hands poised on a keyboard. He is superimposed with a graphic image of a computer screen asking for a password, suggesting he is a hacker.
Share Market News

Another ASX 200 company has been hit with a cyber incident. Here's what we know

Hackers have breached the systems of this ASX 200 company.

Read more »

a woman
Broker Notes

5 ASX 200 shares that inflation can't touch: expert

Regardless of whether you're a bull or a bear, cost pressures are a factor when buying stocks at the moment.

Read more »